Who is sponsoring NCT04401774?

NCT04401774 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT04401774?

Interventions in NCT04401774: Nivolumab.

What condition does NCT04401774 study?

NCT04401774 studies Primary Central Nervous System Lymphoma (PCNSL).

Is NCT04401774 still recruiting?

NCT04401774 is currently completed. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT04401774

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Completed Phase 2 Last updated 27 January 2026

What this trial tests

Phase 2 trial testing Nivolumab in Primary Central Nervous System Lymphoma (PCNSL) in 14 participants. Completed in 22 January 2026.

Timeline

22 May 2020

Primary endpoint
22 January 2026

22 January 2026

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	22 May 2020
Primary completion	22 January 2026
Estimated completion	22 January 2026
Sites	7 locations across United States

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →

Conditions studied

Primary Central Nervous System Lymphoma (PCNSL) — all drugs for Primary Central Nervous System Lymphoma (PCNSL) →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Primary Central Nervous System Lymphoma (PCNSL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) in their CSF despite completion of their first treatment (first-line treatment).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
Minderman M, Amir A, Kraan W, Schilder-Tol EJM, et al · · 2021 · cited 21× · PMID 34125179 · DOI 10.1182/blood.2021011366
Current Trends in Cell-Free DNA Applications. Scoping Review of Clinical Trials.
Stawski R, Stec-Martyna E, Chmielecki A, Nowak D, et al · · 2021 · cited 20× · PMID 34571783 · DOI 10.3390/biology10090906
Liquid biopsy in hematological malignancies: current and future applications.
Talotta D, Almasri M, Cosentino C, Gaidano G, et al · · 2023 · cited 17× · PMID 37152045 · DOI 10.3389/fonc.2023.1164517
Update on Novel Therapeutics for Primary CNS Lymphoma.
Schaff LR, Grommes C. · · 2021 · cited 15× · PMID 34771535 · DOI 10.3390/cancers13215372
Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.
Nayak L, Bettegowda C, Scherer F, Galldiks N, et al · · 2024 · cited 13× · PMID 38598668 · DOI 10.1093/neuonc/noae032
Recent Progress on Primary Central Nervous System Lymphoma-From Bench to Bedside.
Shao L, Xu C, Wu H, Jamal M, et al · · 2021 · cited 13× · PMID 34485125 · DOI 10.3389/fonc.2021.689843
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.
Almasri M, Maher N, Al Deeban B, Diop NM, et al · · 2025 · cited 9× · PMID 40430009 · DOI 10.3390/ijms26104869

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Primary Central Nervous System Lymphoma (PCNSL)

Currently open trials in the same condition.

NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
NCT07410520 — PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. · Phase 2 · recruiting
NCT07198087 — A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impa · Phase 1 · active not recruiting
NCT07188077 — Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma · recruiting
NCT07074470 — Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL · NA · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04401774 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing